Epigenetic and Metabolomic Changes in Childhood Cancer Survivors
Stopped early
Conditions studied: Childhood Cancer
In brief
The purpose of this research study is to try and identify markers in childhood cancer survivors to help predict if they will develop late effects from their cancer treatment.
Key facts
- Study ID
- NCT03866707
- Run by
- Wake Forest University Health Sciences
- People needed
- 7
- Starts
- 2019-02-25
- Expected to finish
- 2020-05-16
- Last updated by the study team
- 2023-12-20
Who can join
Age: 1 and older, up to 18. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Childhood cancer survivors age 1-18 years old who received intensive treatment which included anthracycline and/or alkylating agent chemotherapy.
- Diseases which will be eligible include, high risk or very high risk acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, sarcomas.
- Healthy controls:
- Healthy controls are defined as children ages 1-18 years old who are free from diseases or medical conditions that might be affected by or have an impact on this research study. Healthy controls will be matched with patients for age, sex, ethnicity, geographic region, and tanner stage, since it is known that these factors can affect the epigenetic signature of an individual. Controls will already be having blood drawn as part of their routine care.
You may not qualify if…
- Cancer survivors:
- Patients who have received a bone marrow transplant will not be eligible.
- Healthy controls:
- Age, sex, ethnicity, geographic region, and tanner stage matched controls with any acute or chronic disease will be excluded.
Where it is running
- Comprehensive Cancer Center of Wake Forest University — Winston-Salem, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.